Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Apr 1, 2010 (Vol. 30, No. 7)

Hopes Dashed for Alzheimer's Patients

The Latest Phase III Failure Perpetuates Skepticism about Developing Drugs for AD

  • Success Continues to Be Evasive

    While Flurizan was expected to treat the underlying causes of the disease, the four currently marketed treatments simply alleviate symptoms. Several drugs that aim to prevent plaque production are in Phase III trials.

    No one believes that developing new AD drugs is easy; over 20 have failed Phase III since 2002. AD patients and their physicians, however, are ill-served by the uber-hype engendered by results from poorly controlled clinical trials and pharma company tap dancing.


Readers' Comments

Posted 11/09/2010 by jaypee costal

Alzheimer's disease treatments using omega-3 products were proven ineffective in a study released Tuesday. I found this here: <a title="Medical test eliminates omega-3 benefit for Alzheimer’s" href="http://personalmoneystore.com/moneyblog/2010/11/02/omega-3-fish-oil-alzheimers/">Omega-3 fish oil fails to slow Alzheimer's, study says</a> The study, which sought to demonstrate how omega-3 fatty acids could impede the progress of dementia, could not. Omega-3 fish-oil has been touted as a treatment for Alzheimer’s because individuals with a diet rich in fish demonstrate a lesser tendency to suffer from dementia .


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »